Votrient
Phase 3Small molecule
Votrient is one of 22 small molecule programs targeting Angiosarcoma. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in Angiosarcoma
#DrugCompanyPhaseTrials
1Halaven
EisaiApproved
Adriamycin
PfizerApproved
Taxol
TevaPhase 2
Keytruda
Merck & Co.Phase 2
Votrient
NovartisPhase 2
Libtayo
RegeneronPhase 2
Stivarga
BayerPhase 2
Nexavar
BayerPhase 2
TRC105
TTracon Pharmaceuticals Inc.
Phase 3
Avastin
BBio-Thera Solutions
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Votrient. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTracon Pharmaceuticals Inc.